

PATENT COOPERATION TREATY

PCT

REC'D 15 DEC 2004

WIPO



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P 687 PC00	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/DK 03/00448	International filing date (day/month/year) 27.06.2003	Priority date (day/month/year) 27.06.2002
International Patent Classification (IPC) or both national classification and IPC C12Q1/68		
Applicant AARHUS UNIVERSITET et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 10 sheets, including this cover sheet.
- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
- These annexes consist of a total of 8 sheets.

3. This report contains indications relating to the following items:
- I ☒ Basis of the opinion
 - II ☐ Priority
 - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain documents cited
 - VII ☐ Certain defects in the international application
 - VIII ☐ Certain observations on the international application

Date of submission of the demand 14.01.2004	Date of completion of this report 14.12.2004
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Schmitt, C Telephone No. +49 89 2399-7351 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/DK 03/00448**

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-61 as originally filed

Claims, Numbers

1-31 received on 20.09.2004 with letter of 20.09.2004

Drawings, Sheets

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☒ furnished subsequently to this Authority in written form.
☒ furnished subsequently to this Authority in computer readable form.
☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☒ the claims, Nos.: 32-37
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/DK 03/00448**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application,
☒ claims Nos. 1-21 (all partially), 22-25 (all completely)

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):
☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
☒ the claims, or said claims Nos. 1-21 (all partially), 22-25 (all completely) are so inadequately supported by the description that no meaningful opinion could be formed.
☒ no international search report has been established for the said claims Nos. 1-21 (all partially)

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the Standard.
☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-21 (all partially), 26-31
	No: Claims	-
Inventive step (IS)	Yes: Claims	1-21 (all partially)
	No: Claims	26-31
Industrial applicability (IA)	Yes: Claims	1-31
	No: Claims	-

2. Citations and explanations

see separate sheet

Re Item I

Basis of the report

The basis for this report is amended claims 1-31 filed with the letter dated 20.09.2004.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

III.1. In view of the International Search Report, claims 1-21 were only searched with respect to the polymorphisms RAlⁱ1, RAle6, **AES-1e3**, ASE-1e1 and the XPD-4bp deletion (i.e. examples 1-3 and 10).

The term "**AES-1e3**" is not found in the present application. The present Examination Authority considers therefore that the term "**AES-1e3**" used in Sheet 210 of the ISR is a spelling mistake and should be read "**ASE-1e3**". Furthermore, from the description it appears that the polymorphism **ASE-1e3a** (Table 1c) is localized at position 36926 of SEQ ID NO:1 whereas the polymorphism **ASE-1e3b** is not localized in any of SEQ ID NO: 1 or 2.

In the following, the present Examining Authority, therefore, assumed that the polymorphism **ASE-1e3** which was searched is the polymorphism **ASE-1e3a** localized at position 36926 of SEQ ID NO:1, said sequence of SEQ ID NO:1 being comprised in the sequence of SEQ ID NO:2.

Claims, or parts of claims, relating to subject-matter in respect of which no international search report has been established need not to be the subject of an international preliminary examination (Rule 66.1(e) PCT).

Thus, an opinion on claims 1-21 is only formulated with respect to the subject-matter that was searched, namely with respect to the polymorphisms denoted RAlⁱ1, RAle6, ASE-1e3a, ASE-1e1 and the XPD-4bp deletion, wherein the polymorphism RAlⁱ1 is located at position 15798 in SEQ ID NO 1, the polymorphism RAle6 is located at position 7887 in SEQ ID NO 1, the polymorphism ASE-1e3a is located at position 36926 in SEQ ID NO 1, the polymorphism ASE-1e1 is located at positions 34858 and 36241 in SEQ ID NO 1 and the polymorphism XPD-4bp is located at position 323-326 in SEQ ID NO 2.

III.2. The present application only shows that specific genotypes, i.e. homozygote for RAlⁱ1^A, homozygote for RAlⁱ1^A and RAle6^A, and homozygote for the complete 167 bp fragment (i.e.

XPD-4bp deletion/insertion polymorphism) are associated with basocellular carcinoma (i.e. skin cancer of epithelial origin) or breast cancer (examples 1-3 and 10). These polymorphisms are encompassed by the sequence of SEQ ID NO: 2. No data are given for any of the following polymorphisms denoted RAl1, RAle6, ASE-1e3a, ASE-1e1 and the XPD-4bp as being linked to lung cancer or colon cancer. Furthermore, the application fails to provide any data showing that the polymorphisms ASE-1e3a or ASE-1e1 are linked to basocellular carcinoma or breast cancer.

The description gives guidance to the skilled person how to identify polymorphisms linked to an increase risk of developing cancer on the basis of statistical analysis of the incidence of a particular allele in two groups of individuals with and without cancer, respectively.

However, even if guidance are given in the description how to assess if a certain polymorphism is linked with a risk of developing cancer, the skilled person will have to assess every single polymorphism for its possible association with a certain phenotype.

It is not because two or more particular alleles at two or more neighbouring loci show allelic association (i.e. linkage disequilibrium) that an additional allele of an additional locus which is in close vicinity will also be in linkage disequilibrium. Even if the probability exists, that a further polymorphism, which is in close vicinity with one that has been shown to be associated with a disease, will also be associated with such a disease, the probability that such further polymorphism is not associated with the disease also exists. Thus, the skilled person will have to assess every single polymorphism for its possible association with a certain phenotype.

Even if the present application shows that certain polymorphisms are associated with certain cancers, the skilled person would not be able without undue burden to identify or assess additional polymorphisms for their association with skin cancer, breast cancer, colon cancer and lung cancer.

Claims 1-21 cover subject-matter not sufficiently disclosed in the sense of Article 5 PCT, and therefore are, in addition, not supported by the description within the meaning of Article 6 PCT.

An opinion on novelty and inventive step of claims 1-21 will therefore only be given with respect to the subject-matter that was searched, and appears to be clear and supported.

III.3. Furthermore, the present application only shows that particular polymorphisms or genotypes are linked to an increased risk to skin cancer of epithelial origin or breast cancer (see item **III.2**, above). However, the present application fails to provide any data as to any polymorphism which is linked to the prognosis of a disease, in particular said cancers, or to

the treatment response of an individual suffering from a cancer.

Claims 22-25 are therefore not supported under Article 6 PCT and the application does not meet the requirements of Article 5 PCT.

No opinion on novelty and inventive step will therefore be given for claims 22-25.

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: YIN JIAOYANG ET AL: 'Multiple single nucleotide polymorphisms on human chromosome 19q13.2-3 associate with risk of basal cell carcinoma.'
CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 11, no. 11, November 2002, pages 1449-1453.
- D2: NEXO BJORN A ET AL: 'A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55.'
CARCINOGENESIS, vol. 24, no. 5, May 2003, pages 899-904.
- D3: ROCKENBAUER ESZTER ET AL: 'Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: Tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts.' CARCINOGENESIS, vol. 23, no. 7, July 2002, pages 1149-1153.
- D4: YIN JIAOYANG ET AL: 'Twelve single nucleotide polymorphisms on chromosome 19q13.2-13.3: Linkage disequilibria and associations with basal cell carcinoma in Danish psoriatic patients.'
BIOCHEMICAL GENETICS, vol. 41, no. 1-2, February 2003, pages 27-37.
- D5: BERGAMASCHI DANIELE ET AL: 'iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.'
NATURE GENETICS, vol. 33, no. 2, February 2003, pages 162-167.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK 03/00448

- D6: SHEN M RICHARD ET AL: 'Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans'
CANCER RESEARCH, vol. 58, no. 4, 15 February 1998, pages 604-608.
- D7: VOGEL ULLA ET AL: 'Polymorphisms of the DNA repair gene XPD: Correlations with risk of basal cell carcinoma revisited'
CARCINOGENESIS (OXFORD), vol. 22, no. 6, June 2001, pages 899-904.
- D8: DYBDAHL MARIANNE ET AL: 'Polymorphisms in the DNA repair gene XPD: Correlations with risk and age at onset of basal cell carcinoma'
CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 8, no. 1, January 1999, pages 77-81.
- D9: WO 95 16791 A (UNIV MCGILL ;POIRIER JUDES (CA)) 22 June 1995.
- D10: CHEN PENGCHIN ET AL: 'Association of an ERCC1 polymorphism with adult-onset glioma'
CANCER EPIDEMIOLOGY BIOMARKERS AND PREVENTION, vol. 9, no. 8, August 2000, pages 843-847.
- D11: YANG JIAN-PING ET AL: 'Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor'
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 22, 28 May 1999, pages 15662-15670.
- D12: EP-A-1 146 054 (ONO PHARMACEUTICAL CO) 17 October 2001.
- D13: BREWSTER A M ET AL: 'The association between polymorphisms in the xeroderma pigmentosum group D gene and risk of breast cancer'
AMERICAN JOURNAL OF EPIDEMIOLOGY, vol. 153, no. 11 Supplement, 1 June 2001 (2001-06-01), page S198 XP002261357 Joint Meeting of the Society for Epidemiologic Research, American College of Epidemiology, Epidemiol; Toronto, Canada; June 13-16, 2001 ISSN: 0002-9262
- D14: BUTKIEWICZ DOROTA ET AL: 'Genetic polymorphisms in DNA repair genes and risk

of lung cancer'

CARCINOGENESIS, vol. 22, no. 4, April 2001, pages 593-597.

V.1. Novelty and inventive step of product claims 26-31.

Claims 26-31 are considered new in the sense of Article 33(2) PCT as their features are not disclosed in any available prior art documents.

Independent claim 26 relates to primer or probe selected from SEQ ID NOs: 7-21, wherein, SEQ ID Nos: 7-10 are primers/probes suitable for the detection of RAI1 polymorphism, SEQ ID Nos: 11-14 are primers/probes suitable for the detection of ASE1e1 polymorphism, SEQ ID Nos: 15-17 are primers/probes suitable for the detection of RAI6 polymorphism and SEQ ID Nos: 18-21 are primers/probes suitable for the detection of RAI-5'2 and RAI-5'3 polymorphisms.

As the presently identified polymorphisms denoted ASE1e1, RAI-5'2 and RAI-5'3 lack any feature which could go beyond the well known features common to all polymorphisms, i.e. their possible use as genetic markers, the claimed sequences of SEQ ID Nos: 11-14 and 18-21 do not appear to be associated with any feature which could go beyond the well known features of their possible use to detect polymorphisms, the only underlying technical problem that can be recognised is the provision of further primer or probe suitable for the detection of polymorphisms. To establish inventive activity, the provision of a sequence must be justified by the technical purpose, i.e. by a hitherto unknown or unexpected technical effect, caused by technical features which distinguish the claimed molecules from numerous other ones. Due to the absence of any unexpected defined technical effect (i.e. detection of a specific polymorphisms which are linked to cancer), the provision of the present sequences of SEQ ID Nos: 11-14 and 18-21 amounts to nothing more than an arbitrary selection.

Independent claim 26 is therefore considered to lack an inventive step in the sense of Article 33(3) PCT.

The additional features set out in dependent claims 27-30 are common practice in the art. Claims 27-30 appear also not inventive in the sense of Article 33(3) PCT.

Lastly, the incorporation of not inventive primers or probes into a kit would be obvious to the skilled person. Claim 31 is therefore not inventive in the sense of Article 33(3) PCT.

The applicant attention is drawn to the fact that primers or probes of SEQ ID Nos:7-10, 15-17 appear to be inventive in the sense of Article 33(3) PCT as they have an unexpected effect over the prior art, i.e. they allow the detection of polymorphisms RAlⁱ1 and RAle⁶ which are linked to basocellular carcinoma (i.e. skin cancer of epithelial origin) or breast cancer.

V.2. Novelty and inventive step of claims 1-21.

Documents D6-D8, D13 and D14 disclose various polymorphisms in the XPD gene which are linked to basocellular carcinoma, breast or lung cancers (see abstracts of said documents). However, none of these document discloses the existence of the XPD-4bp polymorphism linked to cancer or suggest that this polymorphism could exist.

Claims 1-21 are thus considered new in the sense of Article 33(2) PCT.

In view of documents D6-D8, D13 and D14, the problem to be solved by claim 1 may be seen as the provision of an alternative method for estimating the basocellular carcinoma or breast cancer risk in an individual.

This problem seems to be solved in view of the overall teaching of the application. None of the available document discloses the features that in combination with D6-D8, D13 or D14 would lead the skilled person to assess specifically the polymorphism sequence RAlⁱ1, RAle⁶ or XPD-4bp.

Hence, claim 1-21 limited to a method for estimating the skin cancer of epithelial origin or breast cancer risk of individual, comprising assessing the presence of the specific genotypes which appear to be linked to said risk, i.e. homozygote for RAlⁱ1^A or for RAlⁱ1^A and RAle^{6A}, and homozygote for the complete 167 bp fragment (i.e. XPD-4bp deletion/insertion polymorphism)(see also item III.2) would appear to involve an inventive step (Article 33(3) PCT).

V.3. Further comments

Trivial names for polymorphisms, such as RAlⁱ1, RAle⁶, ASE-1e3, ASE-1e1 and XPD-4bp are deemed to be unclear in the sense of Article 6 PCT. Said polymorphisms should be clearly defined by their position within SEQ ID NO: 1 or SEQ ID NO:2.

The validity of the priority claimed by the present application has not been checked.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK 03/00448

Should the claimed priority be invalid, then documents D1-D5, cited as P,X documents in the International Search Report, would appear to be highly relevant for the question of novelty and/or inventive step of present claims 1-31.

20-09-2004

14-13 PAA 00020004

BUIDERG A/S

7 SEP MONROE

008 20.09.2004

20-09-2004

Agent's file reference: PAA 000
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

1

10/519505

DT01 Rec'd PCT/DT 27 DEC 2004

Amended Claims

5 1. A method for estimating the skin cancer, lung cancer, breast cancer and colon cancer risk of an individual comprising

- 10
- assessing in the genetic material of a sample from said individual a sequence polymorphism
 - in a region corresponding to SEQ ID NO: 2, or a part thereof, or
 - in a region complementary to SEQ ID NO: 2, or a part thereof, or
 - in a transcription product from a sequence in a region corresponding to SEQ ID NO: 2, or a part thereof, or
 - 15 - or translation product from a sequence in a region corresponding to SEQ ID NO: 2, or a part thereof,
 - obtaining a sequence polymorphism response,
 - estimating the skin cancer, lung cancer, breast cancer and colon cancer risk of said individual based on the sequence polymorphism response.
- 20

25 2. The method according to claim 1, wherein a sequence polymorphism is assessed

- in a region corresponding to SEQ ID NO: 1, or a part thereof, or
- in a region complementary to SEQ ID NO: 1, or a part thereof, or
- in a transcription product from a sequence in a region corresponding to SEQ ID NO: 1, or a part thereof, or
- 30 - or translation product from a sequence in a region corresponding to SEQ ID NO: 1, or a part thereof.

35 3. The method according to claim 1, wherein the cell sample is a blood sample, a tissue sample, a sample of secretion, semen, ovum, a washing of a body surface, such as a buccal swab, a clipping of a body surface, including hairs and nails.

AMENDED SHEET

20.09.2004

14710 PAA 3320384

009 20.09.2004

DK03004

Agent's file reference: PCT/PC00
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

2

4. The method according to any of the preceding claims, wherein the cell is selected from white blood cells and tumor tissue.
5. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least one mutation base change.
6. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least two base changes.
7. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least one single nucleotide polymorphism.
8. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least two single nucleotide polymorphisms.
9. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least one tandem repeat polymorphism.
10. The method according to any of the preceding claims, wherein the sequence polymorphism comprises at least two tandem repeat polymorphisms.
11. The method according to any of the preceding claims, wherein the assessment is conducted by means of at least one nucleic acid primer or probe, such as a primer or probe of DNA, RNA or a nucleic acid analogue such as peptide nucleic acid (PNA) or locked nucleic acid (LNA).
12. The method according to claim 11, wherein the nucleotide primer or probe is capable of hybridising to a subsequence of the region corresponding to SEQ ID NO: 1, or a part thereof, or a region complementary to SEQ ID NO:1.
13. The method according to claim 11, wherein the primer or probe has a length of at least 9 nucleotide or peptide monomers.

AMENDED SHEET

Agent's file reference: P 000
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

3

14. The method according to any of the preceding claims 11-13, wherein at least one primer or probe is capable of hybridising to a subsequence selected from the group of subsequences

- 5 1. GCTCTGAAAC TTAGTAGCCC(A/G)GTATTTATGG AGAGGCATTT
2. GTGGTCAAAT TCTCATT CAT CBTGG (T/C) CCAGGCAAGC
ACACTTCCTC
3. ACCCTGAGGT GAGCACCTGT TCCTT(C/T) TCCTTGCCCT TAGCCCA-
GAG GTAGA
10 4. GGGCAGGGGT TTGTGCCTCC AATGA (G/A) CACAAGCTCC
CCCTGCCCCC CAACT
5. CCTGGCGGTG GCCGTACCA GCTTT (T/C) GGGGGTGTTT
GGGAAGCTGG
6. CTCCAGCCCC ACTGTTCCCT (A/G) GGCCCTATTG GTCCCCCTGG
15 7. ACAAGGAGGA GGCAGAAGTG AGGTT (G/C) AAACCCACTG CCAATC-
TTA
8. CCAACACGGT GAAACCCCGT CTGTA(T/C)TAAAAATACA AAAATTAGCC
9. AATCCAGGAC CCCATAATCT TCCGT (C/T) ATCTAAAACA ATA-
ATGGTGA
20 10. CCAAGGGGG CGAGGGGAGG GTGAA (A/G)GGGTGGGACG
GGGGCAGCCG
11. GAAGTGAGAA GGGGGCTGGG GGTGG (G/-) CGCTCGCTAG
CGGGCGCGGG
12. CGCAGCGCA GTATCCCGAT TGGCT (C/G)TGCCCTAGCG GATT-
GACGGG
25 13. AACTCCTGGG TTCGATCAAT ACTCA (GACA/-) ATCTTGGCAG
GCGCAGGAGG
14. GCTGGGATTA CAGGCTTGAG CCACC (A/G) CGCCCGGCCT
GCAAAGCCAT
30 15. TTTTGTATCT TTAGTAGAGA CAGG (T/G) TTTCTCATG TTGGTCAGGC
16. GCCTCAGCCT CCCGAGTAGC TGAGACT (C/A) CAGGTGCCCG CCAC-
CACGCC
17. TGAAATTGTA GGTGAGAGG CCAGGCG (C/T) GGTGCTCAG
CCTGTAATTT
35 18. GTTTATAAAC ATTAACCAG (T/A) GCTGTGTGAA GGCACCTAAT

Agent's file reference: P000000
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

4

19. CCGTCTCTAT TAAAAATATA AAA (A/C) AATTAGCCG GGTGTAGCGG
20. GGGAGGCTCG AGGCGGGC (A/G) GATTGCATGA GTCAGGATT
21. TCCCAAGTTT CAGGECCTAA (T/G) ATTCTCAAAT CACAGGATT
22. TGCAATGAGC TGAGATCGC (A/G) CCACTGCACT CCAGCCTGGG
5 23. TCTTAGGACG CATGGGGGT (T/G) GAGAGAACGG GGAGATAGAC
24. CTGGGTTCTA GAACTACC (C/T) ATGAAAACCC AGCTGTTTCC
25. ATTCTGCCCT GGGTTCTAGA ACTACCT (C/A) TGCAAACCCA
GCTGTTTCCC
26. GCTGTTTCCC ACCCCATAAG GCA (A/G) TAGGGGAGCC
10 CACCTCCGCC
27. GACCTAGAAG ATCGGTGAG A (C/T) AGCAGCTTGA GGCTGGCAGG
28. CTGGCCAGGA ATGCAGTCGG GTCAC (C/T) CTGTCTAGCC
ACCGTCTCGC
29. GGGAGGAGTC GCGGATCAGG (C/T) CCCTTCTGA AAGTCATCGA
15 30. GCAGCCCGGG CTACAGGGTT (A/G) CCTGAGGTGT GGGTCCCAGG
31. TAGAAATACT AACAAAGGGC (T/C) GTGGGTTTCT CCCCTGCTT
32. ACAGGAGAGG GAAGGTTTTTG (A/T) TTTTTTTTTT GTTTTTTTT
33. GAAGAGGAAG AAGCCCAAAG GGA (A/C) AGAAACCTTC GAGCCA-
GAAG
20 34. GCGCCTCAAC AGCCAGAAGG AGCG (A/G) AGCCTCAGGC CCAGG-
CAGCT
35. TTQAGACTCT CTGTTTGAT (A/G) CTTCACTCAG AAGGTGCTTC
36. AGGCCAGGCT CCTGCTGGCT G (C/G) GCTGGTGAG TCTCTGGGA
37. CCCCTATACC CTCAAGCAT (C/T) TATCCATTGA GTTACAAACA
25 38. ACCATCCCCC GCCTTCCGTT (A/C) GTCCGCCCCC CGAGGCTAGC

or to a sequence complementary to any of the subsequences.

15. The method according to claim 14, wherein at least one nucleotide probe is se-
30 lected from the group consisting of
1. TGAAATTGTA GGTGAGAGG CCAGGCG (C/T) GGTGCTCAG
CCTGTAATTT
2. GTTATAAAG ATTAAACCAG (T/A) GCTGTGTGAA GGCACCTAAT
35 3. CCGTCTCTAT TAAAAATATA AAA (A/C) AATTAGCCG GGTGTAGCGG

20.09.2004

14:14 FAX 00000004

012

20.09.2

B K03004

Agent's file reference: P601400
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

5

- 5 4. GGGAGGCTCG AGGCGGGC (A/G) GATTGCATGA GCTCAGGATT
5. TCCCAAGTTT CAGGGCCCAA (T/G) ATTCTCAAAT CACAGGATTC
6. TGCAGTGAGC TGAGATCGC (A/G) CCACTGCACT CCAGCCTGGG
7. TCTTAGGACG CATGGGGGT (T/G) GAGAGAACGG GGAGATAGAC
8. CTGGGTTCTA GAACTACC (C/T) ATGCAAACCC AGCTGTTTCC
9. ATTCTGCCCT GGGTTCTAGA ACTACCT (C/A) TGCAAACCCA
GCTGTTTCCC
10. GCTGTTTCCC ACCCCATAAG GCA (A/G) TAGGGGAGCC
CACCTCCGCC
10 11. GACCTAGAAG ATCGGTGAG A (C/T) AGCAGCTTGA GGCTGGCAGG
12. CTGGCCAGGA ATGCAGTCGG GTCAC (C/T) CTGTCTAGCC
ACCGTCTCGC
13. GGGAGGAGTC GCCGATCAGG (C/T) CCCTTCCTGA AAGTCATCGA
14. GCAGCCCGGG CTACAGGGTT (A/G) CCTGAGGTGT GGGTCCCAGG
15 15. TAGAAATACT AACAAAGGGC (T/C) GTGGGTTTCT CCCCCTGCTT
16. ACAGGAGAGG GAAGGTTTTTGG (A/T) TTTTTTTTTT GTTTTTTTT
17. GAAGAGGAAG AAGCCCAAAG GGA (A/C) AGAAACCTTC GAGCCA-
GAAG
18. GCGCCTCAAC AGCCAGAAGG AGCG (A/G) AGCCTCAGGC CCAGG-
20 CAGCT

or to a sequence complementary to any of the subsequences.

- 25 16. The method according to claim 15, wherein at least one nucleotide probe is selected from the group consisting of

- 30 1. GTTTATAAAC ATTAAACGAG (T/A) GCTGTGTGAA GGCACCTAAT
2. CCGTCTCTAT TAAAAATATA AAA (A/C) AATTAGCCG GGTTAGCGG
3. GGGAGGCTCG AGGCGGGC (A/G) GATTGCATGA GCTCAGGATT
4. TCCCAAGTTT CAGGGCCCAA (T/G) ATTCTCAAAT CACAGGATTC
5. TGCAGTGAGC TGAGATCGC (A/G) CCACTGCACT CCAGCCTGGG
or to a sequence complementary to any of the subsequences.

AMENDED SHEET

20-09-2002

14:15 FAX 00000004

NOVEMBER 2002

7 SEP 2002

013 20-09-2002

DK03002

Agent's file reference: P63/PC00
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

6

17. The method according to any of the preceding claims, wherein at least one sequence polymorphism is assessed in a region corresponding to SEQ ID NO: 1 position 1521-37752 (r).
- 5 18. The method according to any of the preceding claims, wherein at least one sequence polymorphism is assessed in a region corresponding to SEQ ID NO: 1 position 7760-22885 (RAI).
- 10 19. The method according to any of the preceding claims, wherein at least one sequence polymorphism is assessed in a region corresponding to SEQ ID NO: 1 position 34391- 37752.
- 15 20. The method according to any of the preceding claims, wherein at least two different probes are used, one probe being selected from the probes as defined in any of claims 13-16, and the other probe being capable of hybridising to a sequence different from SEQ ID NO: 1, or a part thereof, or to a sequence complementary to a region different from SEQ ID NO: 1, or a part thereof.
- 20 21. The method according to claim 1, wherein the translational product from a sequence in a region corresponding to SEQ ID NO: 1, or a part thereof, is an antibody, such as a monoclonal or polyclonal antibody.
- 25 22. A method for estimating the disease prognosis of an individual comprising
- assessing in the genetic material of a sample from said individual a sequence polymorphism
- 30 - in a region corresponding to SEQ ID NO: 2, or a part thereof, or
- in a region complementary to SEQ ID NO: 2, or a part thereof, or
- in a transcription product from a sequence in a region corresponding to SEQ ID NO: 2, or a part thereof, or
- or translation product from a sequence in a region corresponding to SEQ ID NO: 2, or a part thereof,
- 35 - obtaining a sequence polymorphism response,

AMENDED SHEET

Agent's file reference: P687-PC00
International application No. PCT/DK03/00448
Applicant Aarhus Universitet et al.

7

- estimating the disease prognosis of said individual based on the sequence polymorphism response.

5 23. The method according to claim 22, wherein the method has any of the features as defined in any of the claims 2-21.

24. A method for estimating a treatment response of an individual suffering from cancer to a disease treatment, comprising

10

- assessing in the genetic material of a sample from said individual a sequence polymorphism

15

- in a region corresponding to SEQ ID NO: 1, or a part thereof, or
- in a region complementary to SEQ ID NO: 1, or a part thereof, or
- in a transcription product from a sequence in a region corresponding to SEQ ID NO: 1, or a part thereof, or
- or translation product from a sequence in a region corresponding to SEQ ID NO: 1, or a part thereof,

20

- obtaining a sequence polymorphism response,

- estimating the individual's response to the disease treatment based on the sequence polymorphism response.

25

25. The method according to claim 24, wherein the method has any of the features as defined in any of the claims 2-21.

26. A primer or probe for detecting polymorphisms for use in a method as defined in any of the claims above, said primer or probe being selected from

30

TGGCTAACACGGTGAAACC (SEQ ID NO:7)
GGAATCCAAAGATTCTATGATGG (SEQ ID NO:8)
GGGAGGCGGAGCTTGCACTGA (SEQ ID NO:9)
CTGAGATCGCACCCTGCAC (SEQ ID NO:10)
GGTTTCTGCTCTGCACACG (SEQ ID NO:11)

35

Agent's file reference: P6614 C00
International application No. PCT/DK03/00448
Applicant: Aarhus Universitet et al.

8

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

27. The primer or probe according to claim 26, wherein the probe is operably linked to at least one label, such as operably linked to two different labels.

15 28. The probe according to claim 27, wherein the label is selected from TEX, TET, TAM, ROX, R6G, ORG, HEX, FLU, FAM, DABSYL, Cy7, Cy5, Cy3, BOFL, BOF, BO-X, BO-TRX, BO-TMR, JOE, 6JOE, VIC, 6FAM, LCRed640, LCRed705, TAMRA, Biotin, Digoxigenin, DuO-family, Daq-family.

20 29. The primer or probe according to any of claims 26-28, wherein the primer or probe is operably linked to a surface.

25 30. The primer or probe according to claim 29, wherein the surface is the surface of microbeads or a DNA chip.

30 31. A kit for use in a method as defined in any of the claims above, comprising at least one primer or probe, said probe being as defined in any of claims 26-30, and optionally further amplifying means for nucleic acid amplification.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.